Home › Companies › ALLOGENE THERAPEUTICS INC. › 2023-2024
Download data (CSV): ballot items · votes by manager · column guide.
Compiled from SEC Form N-PX filings and ALLOGENE THERAPEUTICS INC.’s Form 8-K, filed June 10, 2024 (Item 5.07 on EDGAR). Page generated November 20, 2026.
Meeting of June 5, 2024: 6 items on ALLOGENE THERAPEUTICS INC.’s Form 8-K, filed June 10, 2024: 4 elected · 2 approved.
Notable dissent: 2 directors (13.2%, 12.3% against).
Dissent tiers, on the company’s own Form 8-K tally (support = FOR ÷ (FOR + AGAINST), or FOR ÷ (FOR + WITHHELD) on a withhold ballot; abstentions and broker non-votes excluded): shareholder proposals with 15% support or more are notable, 25% significant, 40% high; director nominees with 10% or more against or withheld are notable, 20% significant; say-on-pay under 80% support is notable, under 70% significant; equity and compensation plans with 15% or more against are notable, 25% significant; any other item the board put forward with 15% or more against is notable. How this is decided
Explore ALLOGENE THERAPEUTICS INC. in the interactive database Compare manager voting policies
These tallies are ALLOGENE THERAPEUTICS INC.’s own, as disclosed to the U.S. Securities and Exchange Commission on Form 8-K, filed June 10, 2024 (Item 5.07, “Submission of Matters to a Vote of Security Holders”). They cover every share voted at the meeting, not just the funds that file Form N-PX.
| Ballot item | For | Against | Abstain | Withheld | Broker non-votes | Support (of votes cast) | Reported outcome | Voting standard |
|---|---|---|---|---|---|---|---|---|
| Elect Director: John DeYoung | 121,177,479 | -- | -- | 17,019,993 | 15,800,932 | 88% | Elected | — |
| Elect Director: Franz Humer, Ph.D. | 119,919,567 | -- | -- | 18,277,905 | 15,800,932 | 87% | Elected | — |
| Elect Director: Joshua Kazam | 127,917,055 | -- | -- | 10,280,417 | 15,800,932 | 93% | Elected | — |
| Elect Director: Stephen Mayo, Ph.D. | 130,166,905 | -- | -- | 8,030,567 | 15,800,932 | 94% | Elected | — |
| 2. Approval, on an Advisory Basis, of the Compensation of the Company's Named Executive Officers | 119,741,038 | 16,298,878 | 2,157,556 | -- | 15,800,932 | 88% | Approved | — |
| 3. Ratification of the Selection of Independent Registered Public Accounting Firm | 152,503,468 | 1,359,400 | 135,536 | -- | 0 | 99.1% | Approved | — |
Source: ALLOGENE THERAPEUTICS INC., Form 8-K, filed with the SEC on June 10, 2024 — read the filing on EDGAR.
See voting trends for Health Care companies, 2023-2024: shareholder support by sector and by company size.
173 asset managers disclosed a vote on at least one ALLOGENE THERAPEUTICS INC. item in their SEC Form N-PX filings. Each item below shows how many of them voted on it, and how. Share totals are the shares those managers' funds voted, summed across every fund they report.
Combines 3 wordings of this item as funds reported it.
87% Majority: yes · of votes cast
Description as filed by funds: Election of Directors: Franz Humer, Ph.D.
ALLOGENE THERAPEUTICS INC.’s own tally for this item (“Elect Director: Franz Humer, Ph.D.”): 119,919,567 for, 18,277,905 withheld, per its Form 8-K filed June 10, 2024 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.
Reported outcome: Elected, in the filing’s own words: “Election of Directors The Company's stockholders elected the four persons listed below as Class III Directors, each to serve until the Company's 2027 Annual Meeting of Stockholders and until their respective successors are duly elected and qualified.”
Support: 87% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.
The 63 asset managers below reported 31,417,352 for, 9,729,946 withheld.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Fidelity | 15,784,639 | 0 | 0 | 681,640 | For |
| Vanguard | 11,538,299 | 0 | 0 | 0 | For |
| T. Rowe Price | 0 | 0 | 0 | 3,466,056 | Withhold |
| PRIMECAP Odyssey Funds | 1,926,671 | 0 | 0 | 0 | For |
| Charles Schwab | 0 | 0 | 0 | 859,326 | Withhold |
| Direxion Shares ETF Trust | 0 | 0 | 0 | 829,338 | Withhold |
| State Street | 783 | 0 | 0 | 772,299 | Withhold |
| Dimensional | 0 | 0 | 0 | 598,915 | Withhold |
| JPMorgan | 591,783 | 0 | 0 | 0 | For |
| BlackRock | 515,139 | 0 | 0 | 0 | For |
| AIG/SunAmerica | 0 | 0 | 0 | 344,081 | Withhold |
| Equitable | 146,911 | 0 | 0 | 191,781 | Mixed |
| TIAA | 0 | 0 | 0 | 273,456 | Withhold |
| Goldman Sachs | 0 | 0 | 0 | 243,287 | Withhold |
| Global X | 194,981 | 0 | 0 | 0 | For |
| Columbia Threadneedle | 170,481 | 0 | 0 | 0 | For |
| SEI | 159,080 | 0 | 0 | 0 | For |
| John Hancock | 0 | 0 | 0 | 149,496 | Withhold |
| Amplify ETF Trust | 0 | 0 | 0 | 147,277 | Withhold |
| Delaware/Macquarie | 0 | 0 | 0 | 146,779 | Withhold |
| ProShares | 0 | 0 | 0 | 140,284 | Withhold |
| American Century | 0 | 0 | 0 | 128,919 | Withhold |
| Lincoln Financial | 32,239 | 0 | 0 | 85,015 | Mixed |
| ALPS ETF Trust | 0 | 0 | 0 | 106,980 | Withhold |
| RMB INVESTORS TRUST | 0 | 0 | 0 | 101,375 | Withhold |
Showing the 25 largest of 63 asset managers. All 63 are in the interactive database (link above).
Combines 4 wordings of this item as funds reported it.
88% Majority: yes · of votes cast
Description as filed by funds: Election of Directors: John DeYoung
ALLOGENE THERAPEUTICS INC.’s own tally for this item (“Elect Director: John DeYoung”): 121,177,479 for, 17,019,993 withheld, per its Form 8-K filed June 10, 2024 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.
Reported outcome: Elected, in the filing’s own words: “Election of Directors The Company's stockholders elected the four persons listed below as Class III Directors, each to serve until the Company's 2027 Annual Meeting of Stockholders and until their respective successors are duly elected and qualified.”
Support: 88% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.
The 63 asset managers below reported 31,480,142 for, 9,667,156 withheld.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Fidelity | 15,784,639 | 0 | 0 | 681,640 | For |
| Vanguard | 11,538,299 | 0 | 0 | 0 | For |
| T. Rowe Price | 0 | 0 | 0 | 3,466,056 | Withhold |
| PRIMECAP Odyssey Funds | 1,926,671 | 0 | 0 | 0 | For |
| Charles Schwab | 0 | 0 | 0 | 859,326 | Withhold |
| Direxion Shares ETF Trust | 0 | 0 | 0 | 829,338 | Withhold |
| State Street | 783 | 0 | 0 | 772,299 | Withhold |
| Dimensional | 0 | 0 | 0 | 598,915 | Withhold |
| JPMorgan | 591,783 | 0 | 0 | 0 | For |
| BlackRock | 515,139 | 0 | 0 | 0 | For |
| AIG/SunAmerica | 0 | 0 | 0 | 344,081 | Withhold |
| Equitable | 146,911 | 0 | 0 | 191,781 | Mixed |
| TIAA | 0 | 0 | 0 | 273,456 | Withhold |
| Goldman Sachs | 0 | 0 | 0 | 243,287 | Withhold |
| Global X | 194,981 | 0 | 0 | 0 | For |
| Columbia Threadneedle | 170,481 | 0 | 0 | 0 | For |
| SEI | 159,080 | 0 | 0 | 0 | For |
| John Hancock | 0 | 0 | 0 | 149,496 | Withhold |
| Amplify ETF Trust | 0 | 0 | 0 | 147,277 | Withhold |
| Delaware/Macquarie | 0 | 0 | 0 | 146,779 | Withhold |
| ProShares | 0 | 0 | 0 | 140,284 | Withhold |
| American Century | 0 | 0 | 0 | 128,919 | Withhold |
| Lincoln Financial | 32,239 | 0 | 0 | 85,015 | Mixed |
| ALPS ETF Trust | 0 | 0 | 0 | 106,980 | Withhold |
| RMB INVESTORS TRUST | 0 | 0 | 0 | 101,375 | Withhold |
Showing the 25 largest of 63 asset managers. All 63 are in the interactive database (link above).
Combines 3 wordings of this item as funds reported it.
93% Majority: yes · of votes cast
Description as filed by funds: Election of Directors: Joshua Kazam
ALLOGENE THERAPEUTICS INC.’s own tally for this item (“Elect Director: Joshua Kazam”): 127,917,055 for, 10,280,417 withheld, per its Form 8-K filed June 10, 2024 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.
Reported outcome: Elected, in the filing’s own words: “Election of Directors The Company's stockholders elected the four persons listed below as Class III Directors, each to serve until the Company's 2027 Annual Meeting of Stockholders and until their respective successors are duly elected and qualified.”
Support: 93% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.
The 63 asset managers below reported 37,097,645 for, 4,049,653 withheld.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Fidelity | 16,466,279 | 0 | 0 | 0 | For |
| Vanguard | 11,538,299 | 0 | 0 | 0 | For |
| T. Rowe Price | 3,466,056 | 0 | 0 | 0 | For |
| PRIMECAP Odyssey Funds | 1,926,671 | 0 | 0 | 0 | For |
| Charles Schwab | 859,326 | 0 | 0 | 0 | For |
| Direxion Shares ETF Trust | 0 | 0 | 0 | 829,338 | Withhold |
| State Street | 783 | 0 | 0 | 772,299 | Withhold |
| Dimensional | 0 | 0 | 0 | 598,915 | Withhold |
| JPMorgan | 591,783 | 0 | 0 | 0 | For |
| BlackRock | 515,139 | 0 | 0 | 0 | For |
| AIG/SunAmerica | 0 | 0 | 0 | 344,081 | Withhold |
| Equitable | 185,184 | 0 | 0 | 153,508 | Mixed |
| TIAA | 273,456 | 0 | 0 | 0 | For |
| Goldman Sachs | 0 | 0 | 0 | 243,287 | Withhold |
| Global X | 194,981 | 0 | 0 | 0 | For |
| Columbia Threadneedle | 170,481 | 0 | 0 | 0 | For |
| SEI | 159,080 | 0 | 0 | 0 | For |
| John Hancock | 108,692 | 0 | 0 | 40,804 | Mixed |
| Amplify ETF Trust | 147,277 | 0 | 0 | 0 | For |
| Delaware/Macquarie | 0 | 0 | 0 | 146,779 | Withhold |
| ProShares | 0 | 0 | 0 | 140,284 | Withhold |
| American Century | 0 | 0 | 0 | 128,919 | Withhold |
| Lincoln Financial | 32,239 | 0 | 0 | 85,015 | Mixed |
| ALPS ETF Trust | 0 | 0 | 0 | 106,980 | Withhold |
| RMB INVESTORS TRUST | 0 | 0 | 0 | 101,375 | Withhold |
Showing the 25 largest of 63 asset managers. All 63 are in the interactive database (link above).
Combines 3 wordings of this item as funds reported it.
94% Majority: yes · of votes cast
Description as filed by funds: Election of Directors: Stephen Mayo, Ph.D.
ALLOGENE THERAPEUTICS INC.’s own tally for this item (“Elect Director: Stephen Mayo, Ph.D.”): 130,166,905 for, 8,030,567 withheld, per its Form 8-K filed June 10, 2024 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.
Reported outcome: Elected, in the filing’s own words: “Election of Directors The Company's stockholders elected the four persons listed below as Class III Directors, each to serve until the Company's 2027 Annual Meeting of Stockholders and until their respective successors are duly elected and qualified.”
Support: 94% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.
The 63 asset managers below reported 38,159,280 for, 2,988,018 withheld.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Fidelity | 16,466,279 | 0 | 0 | 0 | For |
| Vanguard | 11,538,299 | 0 | 0 | 0 | For |
| T. Rowe Price | 3,466,056 | 0 | 0 | 0 | For |
| PRIMECAP Odyssey Funds | 1,926,671 | 0 | 0 | 0 | For |
| Charles Schwab | 859,326 | 0 | 0 | 0 | For |
| Direxion Shares ETF Trust | 0 | 0 | 0 | 829,338 | Withhold |
| State Street | 772,033 | 0 | 0 | 1,049 | For |
| Dimensional | 0 | 0 | 0 | 598,915 | Withhold |
| JPMorgan | 591,783 | 0 | 0 | 0 | For |
| BlackRock | 515,139 | 0 | 0 | 0 | For |
| AIG/SunAmerica | 0 | 0 | 0 | 344,081 | Withhold |
| Equitable | 338,692 | 0 | 0 | 0 | For |
| TIAA | 273,456 | 0 | 0 | 0 | For |
| Goldman Sachs | 0 | 0 | 0 | 243,287 | Withhold |
| Global X | 194,981 | 0 | 0 | 0 | For |
| Columbia Threadneedle | 170,481 | 0 | 0 | 0 | For |
| SEI | 159,080 | 0 | 0 | 0 | For |
| John Hancock | 108,692 | 0 | 0 | 40,804 | Mixed |
| Amplify ETF Trust | 147,277 | 0 | 0 | 0 | For |
| Delaware/Macquarie | 0 | 0 | 0 | 146,779 | Withhold |
| ProShares | 0 | 0 | 0 | 140,284 | Withhold |
| American Century | 0 | 0 | 0 | 128,919 | Withhold |
| Lincoln Financial | 100,039 | 0 | 0 | 17,215 | Mixed |
| ALPS ETF Trust | 0 | 0 | 0 | 106,980 | Withhold |
| RMB INVESTORS TRUST | 0 | 0 | 0 | 101,375 | Withhold |
Showing the 25 largest of 63 asset managers. All 63 are in the interactive database (link above).
Combines 8 wordings of this item as funds reported it.
88% Approved · of votes cast
Prior year: 69.7% for (June 13, 2023 meeting) ▲ 18.3 pts
Description as filed by funds: To approve, on an advisory basis, the compensation of the Company's named executive officers, as disclosed in the proxy statement.
ALLOGENE THERAPEUTICS INC.’s own tally for this item (“2. Approval, on an Advisory Basis, of the Compensation of the Company's Named Executive Officers”): 119,741,038 for, 16,298,878 against — passed, per its Form 8-K filed June 10, 2024 (Item 5.07).
Reported outcome: Approved, in the filing’s own words: “Approval, on an Advisory Basis, of the Compensation of the Company's Named Executive Officers The Company's stockholders approved, on an advisory basis, the compensation of the Company's named executive officers, as disclosed in the proxy statement for the Annual Meeting.”
Support: 88% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.
Fund voting reports and institutional-manager reports both cover this item. An institutional manager can report shares that a fund it advises also reports, so the two are shown separately below and never added together, and their sum is not shown (fund and manager reports combined may count the same shares twice).
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Fidelity | 16,466,279 | 0 | 0 | 0 | For |
| Vanguard | 11,538,299 | 0 | 0 | 0 | For |
| T. Rowe Price | 0 | 3,466,056 | 0 | 0 | Against |
| PRIMECAP Odyssey Funds | 1,926,671 | 0 | 0 | 0 | For |
| Charles Schwab | 0 | 859,326 | 0 | 0 | Against |
| Direxion Shares ETF Trust | 0 | 829,338 | 0 | 0 | Against |
| State Street | 772,033 | 1,049 | 0 | 0 | For |
| Dimensional | 0 | 598,915 | 0 | 0 | Against |
| JPMorgan | 591,783 | 0 | 0 | 0 | For |
| BlackRock | 515,139 | 0 | 0 | 0 | For |
| AIG/SunAmerica | 0 | 344,081 | 0 | 0 | Against |
| Equitable | 146,911 | 191,781 | 0 | 0 | Mixed |
| TIAA | 0 | 273,456 | 0 | 0 | Against |
| Goldman Sachs | 0 | 243,287 | 0 | 0 | Against |
| Global X | 194,981 | 0 | 0 | 0 | For |
| Columbia Threadneedle | 170,481 | 0 | 0 | 0 | For |
| SEI | 159,080 | 0 | 0 | 0 | For |
| John Hancock | 0 | 149,496 | 0 | 0 | Against |
| Amplify ETF Trust | 0 | 147,277 | 0 | 0 | Against |
| Delaware/Macquarie | 0 | 146,779 | 0 | 0 | Against |
| ProShares | 0 | 140,284 | 0 | 0 | Against |
| American Century | 0 | 128,919 | 0 | 0 | Against |
| Lincoln Financial | 100,039 | 17,215 | 0 | 0 | Mixed |
| ALPS ETF Trust | 0 | 106,980 | 0 | 0 | Against |
| RMB INVESTORS TRUST | 0 | 101,375 | 0 | 0 | Against |
Fund voting reports, all 62 managers: 32,943,208 for, 8,204,090 against. Showing the 25 largest; every one is in the interactive database (link above).
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Fidelity | 20,001,060 | 0 | 0 | 0 | For |
| PRIMECAP MANAGEMENT CO/CA/ | 5,567,586 | 0 | 0 | 0 | For |
| T. Rowe Price | 0 | 4,263,806 | 0 | 0 | Against |
| BlackRock | 3,494,275 | 62,179 | 0 | 0 | For |
| Woodline Partners LP | 2,642,690 | 0 | 0 | 0 | For |
| JPMorgan | 2,560,911 | 1,793 | 0 | 0 | For |
| State Street | 1,910,470 | 34,496 | 0 | 0 | For |
| Wildcat Capital Management, LLC | 0 | 0 | 1,920,787 | 0 | Abstain |
| Vida Ventures Advisors, LLC | 1,798,163 | 0 | 0 | 0 | For |
| Vestal Point Capital, LP | 0 | 986,117 | 0 | 0 | Against |
| Charles Schwab | 0 | 859,326 | 0 | 0 | Against |
| Rafferty Asset Management, LLC | 0 | 829,338 | 0 | 0 | Against |
| Two Sigma | 0 | 804,245 | 0 | 0 | Against |
| GEODE CAPITAL MANAGEMENT, LLC | 801,297 | 0 | 0 | 0 | For |
| BBR PARTNERS, LLC | 798,899 | 0 | 0 | 0 | For |
| Citadel | 789,961 | 0 | 0 | 0 | For |
| NORDEA INVESTMENT MANAGEMENT AB | 0 | 742,114 | 0 | 0 | Against |
| Northern Trust | 538,730 | 47 | 0 | 0 | For |
| Cerity Partners LLC | 430,481 | 0 | 0 | 0 | For |
| Coastal Bridge Advisors, LLC | 0 | 386,045 | 0 | 0 | Against |
| Dimensional | 0 | 340,586 | 0 | 0 | Against |
| Nuveen | 0 | 275,144 | 0 | 0 | Against |
| Eaton Vance | 0 | 237,155 | 0 | 0 | Against |
| Mitsubishi UFJ Asset Management Co., Ltd. | 0 | 220,994 | 0 | 0 | Against |
| Goldman Sachs | 0 | 220,645 | 0 | 0 | Against |
Institutional-manager reports, all 125 managers: 42,151,865 for, 11,997,032 against, 1,920,787 abstained, 12,500 not voted. Showing the 25 largest; every one is in the interactive database (link above).
Combines 2 wordings of this item as funds reported it.
99.1% Approved · of votes cast
Prior year: 100.0% for (June 13, 2023 meeting) ▼ 0.8 pts
Description as filed by funds: To ratify the selection by the Audit Committee of the Board of Directors of Ernst & Young LLP as the independent registered public accounting firm of the Company for its fiscal year ending December 31, 2024.
ALLOGENE THERAPEUTICS INC.’s own tally for this item (“3. Ratification of the Selection of Independent Registered Public Accounting Firm”): 152,503,468 for, 1,359,400 against — passed, per its Form 8-K filed June 10, 2024 (Item 5.07).
Reported outcome: Approved, in the filing’s own words: “Ratification of the Selection of Independent Registered Public Accounting Firm The Company's stockholders ratified the selection by the Audit Committee of the Company's Board of Directors of Ernst & Young LLP as the Company's independent registered public accounting firm for the fiscal year ending …”
Support: 99.1% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.
The 63 asset managers below reported 41,147,298 for.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Fidelity | 16,466,279 | 0 | 0 | 0 | For |
| Vanguard | 11,538,299 | 0 | 0 | 0 | For |
| T. Rowe Price | 3,466,056 | 0 | 0 | 0 | For |
| PRIMECAP Odyssey Funds | 1,926,671 | 0 | 0 | 0 | For |
| Charles Schwab | 859,326 | 0 | 0 | 0 | For |
| Direxion Shares ETF Trust | 829,338 | 0 | 0 | 0 | For |
| State Street | 773,082 | 0 | 0 | 0 | For |
| Dimensional | 598,915 | 0 | 0 | 0 | For |
| JPMorgan | 591,783 | 0 | 0 | 0 | For |
| BlackRock | 515,139 | 0 | 0 | 0 | For |
| AIG/SunAmerica | 344,081 | 0 | 0 | 0 | For |
| Equitable | 338,692 | 0 | 0 | 0 | For |
| TIAA | 273,456 | 0 | 0 | 0 | For |
| Goldman Sachs | 243,287 | 0 | 0 | 0 | For |
| Global X | 194,981 | 0 | 0 | 0 | For |
| Columbia Threadneedle | 170,481 | 0 | 0 | 0 | For |
| SEI | 159,080 | 0 | 0 | 0 | For |
| John Hancock | 149,496 | 0 | 0 | 0 | For |
| Amplify ETF Trust | 147,277 | 0 | 0 | 0 | For |
| Delaware/Macquarie | 146,779 | 0 | 0 | 0 | For |
| ProShares | 140,284 | 0 | 0 | 0 | For |
| American Century | 128,919 | 0 | 0 | 0 | For |
| Lincoln Financial | 117,254 | 0 | 0 | 0 | For |
| ALPS ETF Trust | 106,980 | 0 | 0 | 0 | For |
| RMB INVESTORS TRUST | 101,375 | 0 | 0 | 0 | For |
Showing the 25 largest of 63 asset managers. All 63 are in the interactive database (link above).
Ranked separately for each type of Form N-PX report. An institutional manager can report shares that a fund it advises also reports, so the two tables can list the same shares and are never added together. Each is ranked by the shares voted on the item that the most managers of that type reported, shown as a share of the 170,452,967 shares outstanding at the time of that meeting.
| # | Asset manager | % of shares outstanding |
|---|---|---|
| 1 | Fidelity | 9.66% |
| 2 | Vanguard | 6.77% |
| 3 | T. Rowe Price | 2.03% |
| 4 | PRIMECAP Odyssey Funds | 1.13% |
| 5 | Charles Schwab | 0.50% |
| 6 | Direxion Shares ETF Trust | 0.49% |
| 7 | State Street | 0.45% |
| 8 | Dimensional | 0.35% |
| 9 | JPMorgan | 0.35% |
| 10 | BlackRock | 0.30% |
| # | Asset manager | % of shares outstanding |
|---|---|---|
| 1 | Fidelity | 11.73% |
| 2 | PRIMECAP MANAGEMENT CO/CA/ | 3.27% |
| 3 | T. Rowe Price | 2.50% |
| 4 | BlackRock | 2.09% |
| 5 | Woodline Partners LP | 1.55% |
| 6 | JPMorgan | 1.50% |
| 7 | State Street | 1.14% |
| 8 | Wildcat Capital Management, LLC | 1.13% |
| 9 | Vida Ventures Advisors, LLC | 1.05% |
| 10 | Vestal Point Capital, LP | 0.58% |
As disclosed to the SEC in Form 13F (quarter-end holdings of 30 large managers), Schedules 13D and 13G (beneficial ownership above 5%) and the company’s own proxy statement (DEF 14A). Each row gives its source and the date its figure is as of: for Form 13F the quarter end it reports, for Schedules 13D and 13G the filing date, and for the proxy statement the date of its ownership table (or, where that date has not been read, the date the proxy was filed). The rows are therefore not all as of the same day.
| Holder | Shares | % outstanding | Source, as of |
|---|---|---|---|
| Fidelity Management Research LLC | 25,241,499 | 14.81% | Proxy statement (DEF 14A), proxy filed April 23, 2024 |
| Pfizer Inc. | 22,032,040 | 12.93% | Proxy statement (DEF 14A), proxy filed April 23, 2024 |
| David Bonderman | 18,716,306 | 10.98% | Proxy statement (DEF 14A), proxy filed April 23, 2024 |
| TPG GP A, LLC | 18,716,306 | 10.98% | Proxy statement (DEF 14A), proxy filed April 23, 2024 |
| BlackRock | 17,514,674 | 10.28% | Form 13F, quarter ended March 31, 2024 |
| David Chang, M.D., Ph.D. | 10,047,561 | 5.89% | Proxy statement (DEF 14A), proxy filed April 23, 2024 |
| Arie Belldegrun, M.D. | 9,983,329 | 5.86% | Proxy statement (DEF 14A), proxy filed April 23, 2024 |
| State Street | 9,184,011 | 5.39% | Form 13F, quarter ended March 31, 2024 |
| Vanguard Group | 9,020,770 | 5.29% | Form 13F, quarter ended March 31, 2024 |
| T. Rowe Price | 4,177,619 | 2.45% | Form 13F, quarter ended March 31, 2024 |
Percentages above are of 170,452,967 shares outstanding, as reported by ALLOGENE THERAPEUTICS INC. on its Form 10-Q dated March 31, 2024 (see the filing on EDGAR). This is the count contemporaneous with the 2023-2024 meeting, not today’s. Each holding is as of its own filing, which may be dated before or after the meeting.
At ALLOGENE THERAPEUTICS INC.'s shareholder meeting held June 5, 2024, in the 2023-2024 proxy season, 173 asset managers reported votes on at least one of its 6 ballot items in their SEC Form N-PX filings, covering 1,420 separate fund positions. On the most widely held item on that ballot — To approve, on an advisory basis, the compensation of the Company's named executive officers… — ALLOGENE THERAPEUTICS INC.'s filing reports the proposal as approved, with 88% support of the votes cast (FOR divided by FOR plus AGAINST, the conventional basis for proxy support; abstentions, broker non-votes and unvoted shares are excluded because none of them took a side). Source: ALLOGENE THERAPEUTICS INC.'s Form 8-K, Item 5.07, filed with the U.S. Securities and Exchange Commission on June 10, 2024.
Every figure above is derived from filings made with the US Securities and Exchange Commission: Form N-PX, in which registered funds disclose how they voted every proxy and institutional managers disclose their votes on executive pay (say-on-pay, say-on-frequency and golden parachutes), and Form 8-K Item 5.07, in which the company reports its own meeting results. Shares outstanding are taken from ALLOGENE THERAPEUTICS INC.’s 10-Q dated March 31, 2024. This page is a static snapshot rebuilt weekly on November 20, 2026; a live search always shows the current data.
ALLOGENE THERAPEUTICS INC. proxy season coverage: 2023-2024 (this page) · 2024-2025 · 2025-2026.
Proxy Votes Now, “ALLOGENE THERAPEUTICS (ALLO) 2024 Annual Meeting: Vote Results”, https://proxyvotesnow.com/company/allogene-therapeutics-inc/2024 (version of November 20, 2026). Derived from SEC Form N-PX and Form 8-K filings; tables licensed CC BY 4.0. Licence: CC BY 4.0.